REG - Hikma Pharmaceutical - Director/PDMR Shareholding
10/01/2023 09:30
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230110:nRSJ2385Ma&default-theme=true
RNS Number : 2385M Hikma Pharmaceuticals Plc 10 January 2023
Hikma Pharmaceuticals PLC
Notification and public disclosure of transactions by persons discharging
managerial responsibilities
Said Darwazah
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Said Darwazah
2 Reason for the notification
a) Position/status Executive Chairman and CEO
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification Description: Ordinary shares of 10 pence each
code
ID Code: GB00B0LCW083
b) Nature of the transaction Grant of a pledge by Darhold Limited over 500,000 Ordinary Shares of 10 pence
each in Hikma Pharmaceuticals PLC in favour EFG Bank. Darhold Limited is
defined as a Person Closely Associated with the Executive Chairman and CEO,
who is a director and shareholder of Darhold.
c) Price(s) and volume(s) Price(s): £0.00p
Volume(s): 500,000
d) Aggregated information Aggregated volume: 500,000
Price: £0.00p
e) Date of the transaction 9 January 2023
f) Place of the transaction Amman
Mazen Darwazah
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Mazen Darwazah
2 Reason for the notification
a) Position/status Executive Vice Chairman
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification Description: Ordinary shares of 10 pence each
code
ID Code: GB00B0LCW083
b) Nature of the transaction Grant of a pledge by Darhold Limited over 500,000 Ordinary Shares of 10 pence
each in Hikma Pharmaceuticals PLC in favour of EFG Bank. Darhold Limited is
defined as a Person Closely Associated with the Executive Vice Chairman, who
is a director and shareholder of Darhold.
c) Price(s) and volume(s) Price(s): £0.00p
Volume(s): 500,000
d) Aggregated information Aggregated volume: 500,000
Price: £0.00p
e) Date of the transaction 9 January 2023
f) Place of the transaction Amman
Mohammed 'Ali' Al-Husry
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Mohammed 'Ali' Al-Husry
2 Reason for the notification
a) Position/status Non-Executive Director
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification Description: Ordinary shares of 10 pence each
code
ID Code: GB00B0LCW083
b) Nature of the transaction Grant of a pledge by Darhold Limited over 500,000 Ordinary Shares of 10 pence
each in Hikma Pharmaceuticals PLC in favour of EFG Bank. Darhold Limited is
defined as a Person Closely Associated with the Non-Executive Director, who is
a director and shareholder of Darhold.
c) Price(s) and volume(s) Price(s): £0.00p
Volume(s): 500,000
d) Aggregated information Aggregated volume: 500,000
Price: £0.00p
e) Date of the transaction 9 January 2023
f) Place of the transaction Amman
Helen Middlemist
Deputy Company Secretary, responsible for releasing this announcement
10 January 2023
+44 (0) 2073992760
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHGCGDBCBBDGXGRecent news on Hikma Pharmaceuticals
See all newsREG - Hikma Pharmaceutical - Result of AGM
AnnouncementREG - Hikma Pharmaceutical - Trading Statement
AnnouncementREG - Hikma Pharmaceutical - Director/PDMR Shareholding
AnnouncementREG - Hikma Pharmaceutical - Hikma appoints new President of Generics business
AnnouncementREG - Hikma Pharmaceutical - Director/PDMR Shareholding
Announcement